FK506 binding protein12.6 (FKBP12.6) binds to the Ca 2+ release channel ryanodine receptor (RyR2) in cardiomyocytes and stabilizes RyR2 to prevent premature sarcoplasmic reticulum Ca 2+ release. Previously, two different mouse strains deficient in FKBP12.6 were reported to have different abnormal cardiac phenotypes. The first mutant strain displayed sex-dependent cardiac hypertrophy, while the second displayed exerciseinduced cardiac arrhythmia and sudden death. In this study, we tested whether FKBP12.6-deficient mice that display hypertrophic hearts can develop exercise-induced cardiac sudden death and whether the hypertrophic heart is a direct consequence of abnormal calcium handling in mutant cardiomyocytes. Our data show that FKBP12.6-deficient mice with cardiac hypertrophy do not display exercise-induced arrhythmia and/or sudden cardiac death. To investigate the role of FKBP12.6 overexpression for cardiac function and cardiomyocyte calcium release, we generated a transgenic mouse line with cardiac specific overexpression of FKBP12.6 using a-myosin heavy chain (aMHC) promoter. MHC-FKBP12.6 mice displayed normal cardiac development and function. We demonstrated that MHC-FKBP12.6 mice are able to rescue abnormal cardiac hypertrophy and abnormal calcium release in FKBP12.6-deficient mice.
2 FKBP12 (also known as fkbp1a) and FKBP12.6 (also known as fkbp1b) are cytoplasmic proteins that share 85% amino acid identity and a similar tissue distribution. Although FKBP12 is highly expressed in cardiomyocytes, FKBP12.6 is the predominant isoform associated with RyR2. 1, [3] [4] [5] Despite their similarities in protein structure, FKBP12
and FKBP12.6 have distinct roles for normal cardiac function. These differences are clearly illustrated in mice with targeted deletion of FKBP12 or FKBP12.6. Mice homozygous for a null mutation in FKBP12 are embryonic lethal due to aberrant cardiac development. 6 In contrast, FKBP12.6-deficient mice display normal cardiac development and are viable. However, once mature, adult FKBP12.6-deficient mice display abnormal cardiac physiology including either enlarged hearts 7 or exercise-induced cardiac arrhythmias and sudden death. 8 Furthermore, our recent study demonstrated that FKBP12 is a key regulator for cardiac voltage-gated sodium channel. 9 RyR is a large tetrameric calcium release channel and is composed of four identical subunits (560 kDa). The majority of channel modulators interact with N-terminal regulatory ''foot'' region.
1 FKBP12.6 has been shown to regulate RyR2 closure via its interaction with RyR2. [10] [11] [12] [13] [14] Two independent mouse strains deficient in FKBP12.6 had distinctively different abnormal cardiac phenotypes. The first strain (129SvEv/C57 hybrid or 129SvEv inbred background) displayed sexspecific adult cardiac hypertrophy. 7 The second strain (DBA/lacJ inbred background) displayed stress/exercise-induced cardiac sudden death. 8 Interestingly, intracellular calcium release appeared to be altered in both FKBP12.6-deficient mouse models, suggesting that secondary genetic factors may contribute to the final pathogenic 
MATERIALS AND METHODS
Generation of aMHC-FKBP12.6 Transgenic and aMHC-FKBP12.6/FKBP12.6-Deficient Mice FKBP12.6-deficient mice were generated as described previously 7 and were maintained in 129SvEv/C57BL backgrounds. To generate aMHC-FKBP12.6 transgenic mice, an a-myosin heavy chain (aMHC) promoter was used to drive a human FKBP12.6 cDNA (coding region), followed by an SV40 early region transcription terminator/polyadenylation site. A myc epitope tag was added in frame to the 5 0 end of FKBP12.6 cDNA. The myc-epitope tag allowed us to distinguish transgenic FKBP12.6 from endogenous mouse FKBP12.6 and FKBP12. aMHC-FKBP12.6 mice were generated as previously described. 10 To generate mice in which FKBP12.6 was only expressed in the myocardium (i.e., FKBP12.6 was not present in any other tissue), we first cross-bred aMHC-FKBP12. 
Morphological, Histological, and Echocardiogram Analyses
Cardiac structure and function of mice were also assessed by histological analysis and echocardiograph (ECG) as previously described. 16 In brief, the heart weight to body weight ratio (mg/g) was used as a measure of cardiac hypertrophy. Cardiac tissue samples were fixed in 10% formalin in phosphate-buffered saline (pH 7.4), paraffin embedded, and sectioned (8-mm thickness). Sections were further processed and stained using hematoxylin and eosin for regular cardiac histology. ECG analysis was performed as previously described. 17 Two-dimensional guided M-mode ECG was used to measure left ventricular (LV) diastolic and systolic dimensions (LVEDD and LVESD) and septal and posterior wall thickness. These measures were used to derive fractional shortening and estimated LV mass. Beyond standard measures of cardiac chamber size we calculated h/r, which is an eccentricity index that is derived from the mean wall thickness/radius of ventricular end diastole chamber dimension. LV chamber size, h/r ratio, and LV mass were used as markers for ventricular remodeling. Using pulse wave Doppler, aortic ejection times (ET) were measured to determine velocity of circumferential fiber shortening (Vcf) as follows: Vcf = fraction shortening (FS)/ET.
Real Time Quantitative RT-PCR and Western Blot Analyses
Real-time quantitative PCR and Western blot analyses were performed as previously described. 16, 18 The relative expression level was normalized to the reference gene ribosomal protein L7. 16, 18 Antibodies against myc-epitope tag and FKBP12 were from Sigma and Affinity BioReagents, respectively.
Electrocardiogram and Exercise Testing in Mice
We studied the possibility of exercise-induced cardiac arrhythmia and sudden death in FKBP12.6-deficient mice (129SvEv/ C57B6) as previously described in the assessment of FKBP12.6-deficient mice (DBA/LacJ). 8 In brief, five FKBP12.6-deficient and five age-matched littermate wild-type mice (males at 5 months of age) were anesthetized using intraperitoneal injection of ketamine (50 mg/kg) and xylazine (10 mg/kg), and electrocardiogram (ECG) transmitters were implanted in the peritoneum. ECG recordings of ambulatory animals were obtained using radiotelemetry (Data Sciences International) with transmitters implanted in the peritoneum over 72 h before recordings. Continuous recordings were collected for each mouse, but only ECG complexes with clearly defined onset and termination signals were sampled. Standard criteria were used to measure ECG parameters. 19 QT intervals were measured to the end of the biphasic T wave [Tr + Ts; QTc = QTc = QT/(RR/100)]. 20 For stress tests, mice were forced to run on an inclined treadmill until exhaustion and were then intraperitoneally injected with epinephrine (0.1 or 0.5 mg/kg). Heart rates of ambulatory animals were determined by averaging heart rates over 4 h. The genotypes of the mice were not revealed to the investigator until after all measurements were performed and data were analyzed.
Calcium Spark and Calcium Transient Measurement
Single ventricular myocytes from adult mice (4-6 months old) were prepared as previously described 7 and were incubated with 10 mM Fluo-4 AM (Molecular Probes) for 10 min at room temperature, placed in a recording chamber mounted on an inverted microscope (TE300; Nikon), and perfused for 40 min at room temperature with physiological salt extracellular solution (140 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl 2 , 1.2 mM MgCl 2 , 10 mM HEPES, pH 7.4, and 10 mM glucose). Fluo-4 fluorescence was recorded using a laser scanning confocal head (Bio-Rad Laboratories) attached to an inverted microscope (TE-300; Nikon) with a planapo · 60 water immersion objective (1.2 NA.; Nikon). Cells were excited with 488-nm light from a krypton-argon laser and depolarized from -70 mV to -42 mV at the holding potential of TRANSGENIC ANALYSIS OF THE ROLE OF FKBP12.6 -/ -males have a significantly higher cardiac weight and size, and an increased left ventricular wall and ventricular septum thickness when compare to wild-type littermate controls. In contrast, FKBP12.6-deficient females have normal size hearts. (B) Analysis of cardiac hypertrophic markers using quantitative reverse-transcription (RT)-PCR. There is no significant alteration in aMHC, SERCA, pln, bMHC, ANF, and acta1 expression in 5-month-old FKBP12.6-deficient males. MHC, myosin heavy chain promoter; pln, phospholamban; SERCA, sarcoplasmic reticulum Ca 2+ ATPase.
elevated (Fig. 1B) . This observation suggests that FKBP12.6-mediated signaling is linked to physiological, rather than pathological hypertrophy, 24, 25 consistent with FKBP12.6-deficient mice never displaying heart failure, a common end stage for the pathological hypertrophic heart. To determine whether FKBP12.6-deficient males also develop exercise-induced cardiac arrhythmia and sudden death in addition to hypertrophy, we compared conscious ECG parameters in these mutant mice and male littermates (5-6 month old) ( Fig. 2A and 2B To test the FKBP12.6-deficient male for exercise and stressinduced arrhythmia (Fig. 2C and 2D) , we subjected the mutant mice and wild-type controls to a strenuous exercise protocol followed by intraperitoneal injection of epinephrine as previously described. 8, 20 While both groups of mice had elevated heart rates following exercise, no syncope or polymorphic ventricular arrhythmia were observed in either group (n = 5 mice/each genotype). Following intraperitoneal injection of epinephrine, we did not observe differences between the two groups of mice. Again, both groups had elevations in heart rate, but neither FKBP12.6-deficient mice nor wild-type littermates displayed syncope or polymorphic ventricular arrhythmia (n = 5 mice/genotype). These observations indicate that the 129SvEv/C57B6 strain of FKBP12.6-deficient mouse does not develop exercise-induced arrhythmia and sudden death.
Generation and Analysis of MHC-FKBP12.6 Transgenic Mice
We generated transgenic mice in which FKBP12.6 expression was driven by a cardiomyocyte-specific alpha myosin heavy chain (aMHC) promoter (Fig. 3A) . The aMHC promoter has a transient burst of activity in embryonic heart around E9.5-10.5. This cardiac specific promoter is reactivated during early postnatal life and remains persistently high into adulthood. 26 Five transgenic lines carrying the MHC-FKBP12.6 transgene were generated with similar FKBP12.6 expression levels and with normal cardiac development and function. Western blot analysis demonstrated that FKBP12.6 expression in MHC-FKBP12.6 hearts was about seven-to ninefold higher than endogenous FKBP12 (Fig. 3B) . MHC-FKBP12.6 mice developed normally with no cases of premature death. The heart weight versus body weight ratio in MHC-FKBP12.6 mice was normal in both sexes (Fig. 3) . Histological analysis demonstrated that MHC-FKBP12.6 hearts were normal in both ventricles and atria from 1 to 12 months of age. To determine whether MHC-FKBP12.6 mice have altered cardiac function, we performed ECG and Doppler analysis ( Table 1) . Consistent with our histological observations, MHC-FKBP12.6 (n = 6, male, 4 months old) transgenic hearts had normal left ventricular end diastolic and systolic diameter (LVEDD and LVESD), left ventricular mass, percent fraction shortening, and Vcf when compared to littermate controls (n = 4). These data suggest that overexpression of FKBP12.6 does not significantly alter cardiac structure and function.
Rescuing Cardiac Hypertrophy Phenotype by MHC-FKBP12.6 Transgenic Mice FKBP12.6 is ubiquitously expressed. One important question was whether the abnormal cardiac hypertrophy seen in FKBP12.6-deficient mice in 129SvEv/C57B6 background was directly caused by the loss of FKBP12.6 expression in cardiomyocytes. In fact, noncardiac defects were also found in FKBP12.6-deficient mice, such as hypertension 7 and renal hypertrophy.* Our next goal was to determine whether this cardiac hypertrophy was secondary to noncardiac or noncardiomyocyte defects in FKBP12.6-deficient mice. To test this, we generated aMHC-FKBP12.6/ FKBP12.6
-/ -(129SvEv/C57B6) compound mice in which FKBP12.6 transgene was only present in cardiomyocytes. Heart size and cardiac morphology were compared between littermate adult males (5 months old) with different genotypes, aMHC-FKBP12.6/ FKBP12.6 -/ -, FKBP12.6 -/ -, and FKBP12.6 + / -, and wild type. As shown in Fig. 3D , cardiomyocyte-specific expression of FKBP12.6 could prevent cardiac enlargement in FKBP12.6-deficient adult males. This These data indicated that cardiomyocyte-specific expression of FKBP12.6 was able to rescue abnormal calcium release in FKBP12.6-deficient cardiomyocyte (Fig. 4) , which further demonstrated a direct association of FKBP12.6 in regulating calcium release -/ -mice rescued by cardiomyocyte-restricted FKBP12.6 transgenic mice. F/Fo, fluorescence magnitude divided by average prestimulus fluorescence; FWHM, full width at half maximum spark size; rising time (ms), taken from point of rise to peak F/Fo; half decay time (ms), exponential fit of rapid phase of F/Fo decay. (**P < 0.05).
channel RyR2 in cardiomyocyte. Taken together, our data provide additional confirmation and insight on the role of FKBP12.6 in regulating cardiomyocyte calcium release and cardiac function.
DISCUSSION
We have carefully analyzed a cardiac hypertrophy phenotype: a total of 173 FKBP12.6 mutants and littermate control mice (88 males and 65 females in two age groups) were analyzed. We also analyzed ECG records of FKBP12.6-deficient mice under resting and extremeexercise conditions. No exercise-induced cardiac arrhythmia and sudden death were seen in FKBP12.6-deficient mice. We also generated FKBP12.6 transgenic mice and assessed the impact of upregulated FKBP12.6 expression on cardiac function. For the most part, our data were consistent with a recent finding in an inducible FKBP12.6 transgenic line, 28 except that we did not observe significant alteration in Ca 2+ release in the cardiomyocytes isolated from MHC-FKBP12.6 transgenic mice, which could be due to two different transgenic expression systems having been used in the studies. What we observed was the consequence of chronic up-regulation of FKBP12.6, which is different from the temporally controlled upregulation of FKBP12.6 in the inducible transgenic system. 28 By crossing FKBP12.6-deficient mice to MHC-FKBP12.6 transgenic mice, we demonstrate that cardiomyocyte-restricted overexpression of FKBP12.6 prevents cardiac hypertrophy in FKBP12.6-deficient mice. This observation strongly indicates a direct impact of FKBP12.6 on cardiomyocyte and cardiac function. The regulatory role of FKBP12.6 in cardiac function and calcium release in cardiomyocytes via RyR2 has been extensively studied in the past decade. It is believed that FKBP12.6 stabilizes the RyR2, and therefore has a direct impact on cardiac excitation-contraction coupling. 1 Depolarization of the sarcolemma and T-tubules in cardiomyocytes triggers contraction by a dynamic process of calciuminduced calcium release. This release is essential to synchronous and coordinated contraction in the heart. Removal of FKBP12.6 from the RyR2 channel complex either genetically (i.e., knock-out) or pharmacologically with a high dose of FK506 produces a ''leaky'' RyR2 channel, as demonstrated by the increase of channel opening probability in single channel bilayer recording in FKBP12. 
